Naushin Siddiqui, MD
Internal Medicine · Flushing, NYNPI 1639224561
Payments from drug & device makers
Across 313 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- AstraZeneca$734
- Novo Nordisk$523
- Boehringer Ingelheim$333
- Amgen$234
- plus $1K from 25 others
What the payments were for
- Food & beverage$5,821100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,471 |
| GSK | 73 | $1,176 |
| AstraZeneca | 41 | $734 |
| Novo Nordisk | 24 | $523 |
| Boehringer Ingelheim | 16 | $333 |
| Amgen | 11 | $234 |
| Novartis | 9 | $193 |
| Sumitomo Pharma America, Inc. | 4 | $130 |
| Lilly USA, LLC | 6 | $117 |
| IBSA Pharma Inc. | 6 | $117 |
| Merck | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Amarin Pharma, Inc. | 4 | $88 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Pfizer | 3 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Bayer | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $32 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $24 |
| Mannkind Corporation | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Heartflow, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
How this compares
$5,850 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $125,078 |
| EliquisApixaban | 54 | $69,420 |
| FarxigaDapagliflozin Propanediol | 46 | $59,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $46,496 |
| Lactulose | 20 | $34,308 |
| JanuviaSitagliptin Phosphate | 40 | $33,514 |
| GemtesaVibegron | 17 | $23,320 |
| LinzessLinaclotide | 17 | $21,871 |
| OzempicSemaglutide | 19 | $21,806 |
| XareltoRivaroxaban | 20 | $18,395 |
| Repatha SureclickEvolocumab | 23 | $17,543 |
| JardianceEmpagliflozin | 15 | $15,803 |
| JubliaEfinaconazole | 11 | $15,451 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $14,953 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $14,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $117 | $125,07883 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $734 | $74,38859 claims |
| PfizerEliquis | $43 | $69,42054 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,176 | $60,22167 claims |
| MerckJanuvia, Janumet | $98 | $44,53654 claims |
| AbbVieLinzess, Synthroid | $1,471 | $34,701212 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $130 | $23,32017 claims |
| Novo NordiskOzempic | $523 | $21,80619 claims |
| Boehringer IngelheimJardiance | $333 | $15,80315 claims |
| Esperion Therapeutics, Inc.Nexlizet | $38 | $14,11714 claims |
| NovartisEntresto | $193 | $11,95911 claims |
| IBSA Pharma Inc.Tirosint-Sol | $117 | $3,23323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.